KIT and melanoma: Several clinical trials are testing novel TKIs and combinations of TKIs with other systemic therapies for melanomas, such as NCT02071940, which involves evaluating PLX3397 (plexidartinib, a multi-target TKI) in advanced KIT mutant acral and mucosal melanomas.